Evonik and InVitria form strategic partnership to supply animal-free albumin to global biopharma market
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Uncontrolled diabetes in pregnancy dramatically increases the risk of pre-eclampsia, stillbirth, birth injuries, and long-term cardiometabolic diseases
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Fenebrutinib targets cells in the immune system known as B cells and microglia
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
Relmada expects to initiate its Phase 3 program in the first half of 2026
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Subscribe To Our Newsletter & Stay Updated